ARS Pharma reports $72.2M neffy sales in first full year; net loss $171.3M

ARS Pharmaceuticals, Inc.

Full-year U.S. neffy net product revenue $72.2M; total revenue $84.3M including $9.7M partner revenue.
FY 2025 net loss $171.3M ($1.74/sh); Q4 net loss $41.3M ($0.42/sh).
Cash $245.0M at Dec 31, 2025; expects to fund operations through cash-flow break-even.
Sales force to expand from 106 to 150 in Q2 2026; >22,500 HCPs prescribed neffy, 50% repeat.
Phase 2b CSU trial interim data H2 2026; Canada approval expected Q2 2026 with ALK.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

ARS Pharmaceuticals, Inc. reported financial results for quarter and year ended December 31, 2025.

Period: quarter and year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 9, 2026, ARS Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2025 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.

View on SEC.gov

171 earnings releases filed in the last 30 days. Browse all earnings releases →

ARS Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-097467

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.